文献速递肺外科心外重症与机械循环支持

EKOS超声辅助溶栓治疗中高危肺栓塞的PERT引导队列研究

Outcomes of EKOS (Ultrasound-Assisted Thrombolysis) for Intermediate-High-Risk Pulmonary Embolism: A PERT-Guided Cohort Study.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-01-01

该单中心回顾性研究纳入128例中高危肺栓塞患者,在PERT路径下接受EKOS超声辅助导管定向溶栓。干预后RV/LV比值与生物标志物显著改善,60天生存概率96.9%,院内恶化主要与基线疾病严重程度相关。

要点

  • EKOS治疗后RV/LV比值中位数从1.6降至1.0,BNP从2365降至877 pg/mL。
  • 60天生存概率为96.9%,短期生存良好。
  • 院内需升级器官支持的恶化主要与基线疾病严重程度相关。

核心结论

  • 在真实世界PERT引导队列中,EKOS与中高危肺栓塞患者快速生理改善和良好短期生存相关。
  • 研究结果为描述性单中心经验,需谨慎解读。

研究设计与样本

  • 回顾性单中心分析,纳入2017年8月至2023年12月连续128例急性中高危肺栓塞患者。
  • 所有患者在结构化PERT路径下接受EKOS引导的超声辅助导管定向溶栓。

主要发现

  • 干预后RV/LV比值和生物标志物显著改善,RV/LV比值中位数从1.6降至1.0(P < .001)。
  • BNP从2365降至877 pg/mL(P < .001)。
  • 部分患者发生需升级器官支持的临床有意义院内恶化,主要与基线疾病严重程度相关。
  • 60天生存概率为96.9%。

关键数值与推荐

  • 复合终点包括死亡、ECMO、肾脏替代治疗或有创机械通气。
  • 多变量逻辑回归用于识别复合终点的决定因素。

临床怎么用

  • 对于中高危肺栓塞患者,在PERT路径下可考虑EKOS超声辅助溶栓以快速改善右心功能和生物标志物。
  • 需关注基线疾病严重程度高的患者,其院内恶化风险较高。

局限性

  • 回顾性单中心设计,结果应作为描述性经验解读。
  • 样本量有限,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Acute intermediate-high-risk pulmonary embolism (PE) is associated with right-ventricular (RV) dysfunction, biomarker elevation, and risk of early clinical deterioration. Ultrasound-assisted catheter-directed thrombolysis (USAT) using the Eko Sonic Endovascular System (EKOS) system is increasingly used in selected patients; however, real-world data on physiological response and clinically relevant in-hospital outcomes remain limited. METHODS: We conducted a retrospective single-centre analysis of 128 consecutive patients with acute intermediate-high-risk PE treated with EKOS-guided USAT within a structured Pulmonary Embolism Response Team (PERT) pathway between August 2017 and December 2023. Changes in RV/LV ratio, B-type natriuretic peptide (BNP), and cardiac troponin before and after intervention were assessed. A composite end-point of death, extracorporeal membrane oxygenation (ECMO), renal replacement therapy, or invasive mechanical ventilation captured clinically meaningful deterioration. Multivariable logistic regression identified determinants of the composite end-point. RESULTS: RV/LV ratio and biomarkers improved significantly after intervention. Median RV/LV ratio decreased from 1.6 to 1.0, and BNP declined from 2365 to 877 pg/mL (both P < .001). Clinically meaningful in-hospital deterioration requiring escalation of organ support occurred in a subset of patients and was predominantly associated with baseline disease severity. Short-term survival remained favourable (60-day probability 96.9%). CONCLUSIONS: In this real-world, PERT-guided cohort, EKOS was associated with rapid physiological improvement and favourable short-term survival in patients with intermediate-high-risk PE. These findings should be interpreted as descriptive single-centre experience.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ali MNHE, Zayat R, Hatam N, et al. Outcomes of EKOS (Ultrasound-Assisted Thrombolysis) for Intermediate-High-Risk Pulmonary Embolism: A PERT-Guided Cohort Study. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42234536. doi:10.1093/icvts/ivag168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。